These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
996 related articles for article (PubMed ID: 25646886)
1. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance. Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886 [TBL] [Abstract][Full Text] [Related]
2. Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK. Oh YJ; Kim HY; Lee MH; Suh SH; Choi Y; Nam TG; Kwon WY; Lee SY; Yoo YH Mol Pharmacol; 2018 Dec; 94(6):1401-1411. PubMed ID: 30366981 [TBL] [Abstract][Full Text] [Related]
3. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease. Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044 [TBL] [Abstract][Full Text] [Related]
4. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. Zhu LH; Wang A; Luo P; Wang X; Jiang DS; Deng W; Zhang X; Wang T; Liu Y; Gao L; Zhang S; Zhang X; Zhang J; Li H J Hepatol; 2014 May; 60(5):1046-54. PubMed ID: 24445216 [TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6. Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567 [TBL] [Abstract][Full Text] [Related]
6. FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease. Zhang C; Chen F; Feng L; Shan Q; Zheng GH; Wang YJ; Lu J; Fan SH; Sun CH; Wu DM; Li MQ; Hu B; Wang QQ; Zhang ZF; Zheng YL Mol Med; 2019 Jun; 25(1):29. PubMed ID: 31215394 [TBL] [Abstract][Full Text] [Related]
7. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855 [TBL] [Abstract][Full Text] [Related]
8. Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance. Qiu Y; Sui X; Zhan Y; Xu C; Li X; Ning Y; Zhi X; Yin L Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):978-990. PubMed ID: 28153708 [TBL] [Abstract][Full Text] [Related]
9. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease. Fu D; Cui H; Zhang Y Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812 [TBL] [Abstract][Full Text] [Related]
11. Hepatic STAMP2 alleviates polychlorinated biphenyl-induced steatosis and hepatic iron overload in NAFLD models. Kim HY; Park CH; Park JB; Ko K; Lee MH; Chung J; Yoo YH Environ Toxicol; 2022 Sep; 37(9):2223-2234. PubMed ID: 35616167 [TBL] [Abstract][Full Text] [Related]
12. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141 [TBL] [Abstract][Full Text] [Related]
13. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. Yamaguchi K; Nishimura T; Ishiba H; Seko Y; Okajima A; Fujii H; Tochiki N; Umemura A; Moriguchi M; Sumida Y; Mitsuyoshi H; Yasui K; Minami M; Okanoue T; Itoh Y Liver Int; 2015 Feb; 35(2):550-61. PubMed ID: 25066281 [TBL] [Abstract][Full Text] [Related]
14. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. Zhuge B; Li G Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687 [TBL] [Abstract][Full Text] [Related]
15. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo. Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952 [TBL] [Abstract][Full Text] [Related]
16. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ. Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935 [TBL] [Abstract][Full Text] [Related]
17. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Wu L; Liu Y; Zhao Y; Li M; Guo L Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490 [TBL] [Abstract][Full Text] [Related]